Latham & Watkins Advises Aratana Therapeutics

Aratana Therapeutics, Inc. (PETX), a pet therapeutics company, has announced the upsizing and pricing of its previously announced public offering. As detailed in the press release below issued by the company, the size of the offering has been increased from 5,500,000 shares of common stock to 6,500,000 shares of common stock at a price to the public of $­­­­­­­19.00 per share.  The company also announced (second press release below) the full exercise of the underwriters' option to purchase 975,000 additional shares of common stock, comprised of 150,000 shares of common stock being sold by Aratana and 825,000 shares of common stock being sold by a selling stockholder. With the exercise of the underwriters' option, gross proceeds to Aratana from the offering are expected to be $97.85 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aratana Therapeutics.

The Latham team advising Aratana in the IPO and follow-on offering is led by partners Peter Handrinos in Boston and Shayne Kennedy in Orange County, with associates Daniel Rees and Richard Kim in Orange County and Erin Gallery in Boston. Advice has also been provided on tax matters by partner Sam Weiner and associate Tali Weiss in Los Angeles; on employee benefits matters by partner David Della Rocca and associate Matthew Conway in Washington, D.C.; and on intellectual property matters by partner Judith Hasko and associate Lee Baker in Silicon Valley.